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Direct treatment costs of 
HIV/AIDS in Portugal
Custos diretos com tratamento do 
VIH/SIDA em Portugal
ABSTRACT
OBJECTIVE: To analyze the direct medical costs of HIV/AIDS in Portugal 
from the perspective of the National Health Service.
METHODS: A retrospective analysis of medical records was conducted for 150 
patients from five specialized centers in Portugal in 2008. Data on utilization of 
medical resources during 12 months and patients’ characteristics were collected. 
A unit cost was applied to each care component using official sources and 
accounting data from National Health Service hospitals.
RESULTS: The average cost of treatment was 14,277 €/patient/year. The main 
cost-driver was antiretroviral treatment (€ 9,598), followed by hospitalization 
costs (€ 1,323). Treatment costs increased with the severity of disease from 
€ 11,901 (> 500 CD4 cells/µl) to € 23,351 (CD4 count ≤ 50 cells/ µl). Cost 
progression was mainly due to the increase in hospitalization costs, while 
antiretroviral treatment costs remained stable over disease stages.
CONCLUSIONS: The high burden related to antiretroviral treatment is 
counterbalanced by relatively low hospitalization costs, which, however, 
increase with severity of disease. The relatively modest progression of total 
costs highlights that alternative public health strategies that do not affect 
transmission of disease may only have a limited impact on expenditure, since 
treatment costs are largely dominated by constant antiretroviral treatment costs.
DESCRIPTORS: Acquired Immunodeficiency Syndrome, economics. Anti-
HIV Agents, economics. Health Care Costs. Economics, Medical.
Artigos Originais DOI:10.1590/S0034-8910.2013047004598
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HIV/AIDS represents a high financial burden for high- 
and low-income countries, due to the high costs of 
antiretroviral therapy (ART), treatment of opportunistic 
infections, lost productivity and declines in human 
capital investment.2 However, many countries have little 
or poorly-validated evidence about costs of HIV/AIDS.5
Measuring the cost of treating HIV-infected persons 
is of particular importance. Ensuring universal and 
high-quality treatments at reasonable cost is a major 
objective of policy makers. Given the adverse economic 
climate, it is more essential than ever before that policy 
makers have access to credible economic evidence and 
reliable forecasts in making future resource allocation 
decisions. “Hot” questions concern the opportunity 
for expanded testing and early detection, pre-exposure 
prophylaxes, regular lab tests for CD4 cell count and 
viral load, choice of regimen options and treatment 
initiation thresholds in the HIV area.3,10,11,13 These 
complex issues require valid figures on treatment costs. 
As Schackman et al12 indicate, “if policy makers rely 
on outdated estimates of HIV care costs, treatment 
programs will be under-funded and the economic value 
of HIV prevention will be understated” (p.990).
RESUMO
OBJETIVO: Analisar dos custos diretos médicos com VIH/SIDA, de acordo 
com a perspetiva do Serviço Nacional de Saúde, em Portugal.
MÉTODOS: Efetuou-se análise retrospectiva de registros médicos em amostra 
de 150 pacientes de cinco centros especializados em 2008. Foram obtidos dados 
de utilização de recursos médicos durante 12 meses e das características dos 
pacientes nesse período. Aplicou-se o custo unitário a cada componente de 
custo, usando fontes oficiais e dados contabilísticos dos hospitais.
RESULTADOS: O custo médio anual de tratamento foi de 14.277 euros por 
paciente. A parcela de custo mais importante foi o custo com o tratamento 
antirretroviral (9.598 euros), seguido dos custos de internação (1.323 euros). Os 
custos de tratamento com severidade aumentaram de 11.901 euros (> 500 CD4 
células/µl) para 23.351 euros (CD4 ≤ 50 células/µl). A progressão dos custos 
deve-se principalmente ao aumento dos custos de internação, dado que os custos 
com tratamento antirretroviral se mantêm constantes ao longo dos estádios.
CONCLUSÕES: O custo elevado do tratamento antirretroviral é compensado 
com o custo relativamente baixo da internação, apesar deste aumentar com a 
severidade. A baixa progressão dos custos totais revela que estratégias de saúde 
pública alternativas que não alterem a transmissão da doença terão apenas 
impacto limitado nas despesas, dado que os custos são largamente influenciados 
pelo do tratamento antirretroviral.
DESCRITORES: Síndrome de Imunodeficiência Adquirida, economia. 
Fármacos Anti-HIV, economia. Custos de Cuidados de Saúde. 
Economia Médica.
INTRODUCTION
Precise knowledge of treatment costs is indispensable in 
planning future health expenditures, producing budget 
impact analyses and defining financing policies. It is 
particularly relevant to identify the major cost drivers 
and the patients’ characteristics that most influence 
treatment expenditures. Estimating how severity affects 
treatment costs can help predict future expenditures for 
different epidemiologic scenarios and screening policies; 
estimating the weight of hospitalization costs can help 
set adequate reimbursement schemes for hospitals and 
potential savings from shifting towards more out-patient 
care; international comparisons of ART costs can help 
identify differences in practices and pricing rules.
Levy et al5 observed in their review of the literature cost 
variations across studies, essentially related to different 
sources, estimation methods and populations. However, 
there is a positive relationship between costs and severity 
of disease (measured by the CD4 cell count). Chen et al1 
find a cost variation from $ 13,885 (CD4 count ≥ 350 
cells/μL) and $ 36,532 (CD4 count < 50 cells/μL) for the 
United States (US) per year. Schackman et al12 measure 
substantial variation across severity groups (from $ 2,000 
to $ 4,700 per month) also for the US. Sloan et al13 
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observe average yearly costs varying between € 15,970 
(CD4 counts of 351-500 cells/μL) and € 36,540 (CD4 
counts < 50 cells/μL) for France. A study in Belgium 
shows variations between € 809 and € 3,551 per month.a
ART drugs are the major cost driver, although their 
weight decreases in the most severe cases. Sloan et al13 
observe that ART drugs represent 76% of total costs, 
with a variation between 81% among the least severely-
affected patients (CD4 counts > 500 cells/μL) and 41% 
among the most-affected ones. Chen et al1 show that 
ART represents 68% of total costs for patients above 
350 CD4 cells/μL, while it falls to 30% for the most 
severely affected patients (< 50 CD4 cells/μL), for 
whom inpatient treatment and other drugs represent the 
major cost component (64%). ART drugs represented 
63% of total cost for Canada in 2005-2006, for 15% 
for inpatient care.4 A common pattern in these studies 
is that ART cost is relatively stable across CD4 strata, 
hence the major source of increase is due to other drugs 
and hospitalizations. Sloan et al13 and Krentz et al,4 who 
both consider longer periods, show that ART-related 
costs have been quite stable over time; hence, the 
small increases in yearly costs are essentially due to 
other components, with marked effects at later stages 
of disease. Recent contributions clarify the role of late 
presentation in substantially increasing immediate costs 
after treatment initiation.13
The perspective is that of the National Health Service 
(NHS), given that private facilities did not treat HIV 
cases at the time our study was performed. The 2011 
Portuguese GDP per capita adjusted for inflation and 
purchasing power parity ($ 21,414) is lower than 
that of other high-income countries for which similar 
analyses have been performed, namely Belgium 
($ 33,217), France ($ 29,938), Germany ($ 34,581), 
Italy ($ 27,053), Switzerland ($ 39,600), and the US 
($ 42,385).b Despite lower wealth and healthcare 
expenditures per capita, coupled with NHS and 
hospitals’ solvency problems, timely universal access 
to innovative drugs is guaranteed at unit costs that are 
comparable to those prevailing in richer European 
countries. In the present study we question (i) whether 
treatment costs differ in this context of scarcer 
resources, similar, e.g., to that prevailing in Eastern 
Europe countries; (ii) whether the potentially high 
burden of ART is compensated by hospitals through 
lower resource use in other care components; (iii) 
whether differences in cost composition affects the 
cost distribution across patients’ groups. Portugal is 
the country in Western Europe with the highest rate 
of new cases and HIV-related mortality, so that high 
unit treatment costs likely transfer into high global 
expenditures.c
This study aimed to analyze the direct medical costs of 
HIV/AIDS in Portugal.
METHODS
A retrospective analysis of patient records was conducted 
in five HIV-AIDS specialized treatment centers in 
Portugal from January 1, 2008 to December 31, 2008. 
This period (12 months) was chosen to cover the relevant 
costs associated with medical practices and follow-up 
management at different stages of the disease.
Specialized centers were chosen representing 38.1% of 
the total patients following consultations in Portugal 
(Table 1). Given that the data collection was based on 
medical records, our sample was limited to 150 records. 
The number of records collected per hospital was 
proportional to their representativeness with respect 
to the total number of patients.
The following inclusion criteria were adopted: known 
HIV infection before January 1, 2008, being at least 18 
years old and not suffering from severe psychological 
disease or severe mental disability, having received 
regular care in the center (at least two episodes of 
inpatient or outpatient resource use per year) during the 
study period, not being transferred to or from another 
hospital during the year, and having provided informed 
Table 1. Sample size and representativeness. Portugal, 2007.
Hospital Patients under treatment in 2007 (n) % Records (n)
Hospital de Santa Maria (CH Lisboa Norte) 2,490 12.7 35
Hospital de São João 1,590 8.1 34
Hospital Egas Moniz (CH Lisboa Ocidental) 1,650 8.2 28
Hospitais Universidade Coimbra 941 4.8 25
Centro Hospitalar de Setúbal 830 4.2 24
Total 146
a Caekelbergh K, Moeremans K, Annemans L, et al. Cost of care for HIV/AIDS in Belgium according to disease stage. Poster session presented at 
the 11th European AIDS Conference/EACS; 2007 Oct 24-27; Madrid, Spain. 
b Organization for Economic Co-Operation and Development. OECD.StatExtracts: Gross domestic product - GDP [cited 2013 Apr 7]. Available 
from: http://stats.oecd.org/Index.aspx?DatasetCode=SNA_TABLE1 
c European Centre for Disease Prevention and Control; WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2009. Stockholm; 2010.
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consent. A list of eligible patients meeting the inclusion 
criteria of the study was produced by the center. We 
ranked the patients into four groups based on the CD4 
cell count and selected an equal number of patients 
from each group at random. We marked the selected 
patients on the screening list and sent the list back to the 
investigator. The investigator requested informed consent 
from the patients and collected the data on that patient.
Inpatient resource use data was collected on a “per 
hospitalization” level. Outpatient resource use data 
was collected on a “per consultation” level. The 
resource use was collected for each inpatient episode 
or outpatient consultation and allocated to the day of 
its occurrence. The data were by the medical staff from 
the participating center, with confidentiality guaranteed.
Items collected from the patient files included (i) 
patient’s demographic and clinical characteristics; (ii) 
outpatient resource use (HIV-related specialists and 
other physicians’ consultations, nurse, physiotherapist 
and social assistant consultations, emergency visits, lab 
tests, ART drugs, prophylactic drugs for opportunistic 
infections and other non-antiretroviral (ARV) drugs); 
(iii) inpatient resource use (hospital stays related to HIV/
AIDS or to opportunistic infections, with associated 
All-Patient Diagnosis Related Groups (AP-DRG).
As regards ART drugs, we assumed that drugs 
were taken until the next consultation. If the next 
consultation occurred after more than 120 days, 
considered the maximum time between consultation 
following Portuguese Guidelines for HIV Treatment, 
we considered the therapy was followed for 120 
days.d As for non-ART drugs, when no information 
was available, length of treatment was given by the 
summary of product characteristics approved by the 
Therapeutic Compendium.e For patients at stages 4, 
5 and 6, some drugs were taken as prophylaxy. The 
assumed length of treatment for each medication, as 
prophylactic or normal treatment, was discussed with 
medical researchers. Complete data on resource use for 
each item can be provided on demand. Due to invalid 
responses on resource use, four questionnaires were 
excluded from the sample.
Total costs were computed by multiplying each resource 
item by its unit value. Unit costs for consultations were 
obtained from the 2006 analytical accounting of the 
Administração Central do Sistema de Saúde – ACSSf 
(National System of Health, Central Adminsitration). The 
drugs were evaluated using the ACSS catalog of public 
health supply, which lists information on unitary costs of 
goods and services acquired in the public health sector 
procurement contracts.g Since most drugs used in the study 
were provided at the hospital, this catalog represented the 
d Coordenação Nacional para a Infecção de VIH/Sida. Recomendações portuguesas para o tratamento da infecção VIH-Sida. Lisboa; 2009. 
e Infarmed. InfoMed: base de dados de medicamentos. Governo de Portugal, Ministério da Saúde, Autoridade Nacional do Medicamento e 
Produtos de Saúde [cited 2011 Mar 31]. Available from: http://www.infarmed.pt/infomed/inicio.php 
f Administração Central do Sistema de Saúde. Contabilidade analítica 2006: hospitais do SNS. Lisboa; 2007. 
g Administração Central do Sistema de Saúde. Catálogo de aprovisionamento público da saúde. Lisboa, Portugal [cited 2011 Mar 31]. Available 
from: http://www.catalogo.min-saude.pt/caps/publico/default.asp
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Figure. Components of average costs per patient year, per stage of disease. Portugal, 2008.
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most adequate information source. As regards other drugs 
not provided at hospitals, we used the reference price 
available in the Therapeutic Compendium, which lists 
pharmacy retail prices. Inpatient stays (AP-DRGs), exams, 
laboratory tests and complementary means of diagnostic 
were valued by official sources (Decree 839-A/2009 of 31 
July 2009). Complete data on the valuation of each item 
can be provided on demand.
In addition to computing average yearly costs per cost 
component and stage of disease, a multivariate analysis 
was performed to estimate the cost determinants. Cost 
data in our sample were right-skewed (skewness = 1.64) 
and heavy tailed (kurtosis = 5.94), which is the 
common pattern of cost distributions in the literature.8 
Normality is rejected using the Shapiro-Wilk test 
(x2 = 40.41; p < 0.05). Non-negativity also renders 
the use of ordinary least square (OLS) inadequate.
We used Generalized Linear Models (GLM) and adopt 
the Manning & Mullahy7 algorithm for choosing 
adequate distribution. The Ordinary Least Squares 
model was not rejected because the heavy-tailed 
log-scale residuals (kurtosis > 3). That model has logged 
costs and also performs better in terms of goodness-
of-fit. The following covariates were included: stage 
of disease, age, sex, transmission category, detection 
setting, hospital and number of comorbidities.
This study was approved by the Comissão Nacional de 
Protecção de Dados (Portugal), Process no. 741/2010, 
authorization 923/2010. It was also approved by the 
Ethical Commissions of the five specialized centers 
involved in the data collection.
RESULTS
The sample were composed by 146 patients (77.0% 
men), 50.0% of whom were < 40 years (Table 2). The 
main transmission category was heterosexual contact, 
followed by intravenous drug use. The detection settings 
were mainly hospitals and primary care centers. The 
average CD4 count at the detection in the sample was 
292.3 cells/µl. The patients’ distribution across severity 
groups (based on CD4 count) during the year was almost 
equal across groups due to our sampling method. A 
large variety of ART regimens was found (29), among 
which the most common were: two nucleoside reverse-
transcriptase inhibitors + one protease inhibitor, and 
two nucleoside reverse-transcriptase inhibitors + one 
non-nucleoside reverse-transcriptase inhibitors.
Taking all patients together, major costs were related to 
ART treatments (€ 9,598/patient/year, 67.0% of total cost), 
followed by HIV consultations (€ 1,323, 9.0% of total cost), 
and hospitalization costs (€ 1,400, 10.0% of total cost), 
giving a cost of € 14,277/patient/year (Table 3). Other 
components included other drugs (7.0%), exams (6.0%) 
and one-day care (2.0%).
Table 2. Characteristics of the sample, Portugal, 2008.
Characteristic Frequency %
Sex
Female 32 21.9
Male 113 77.4
Missing 1 0.7
Age category
≤ 30 15 10.3
31 to 40 58 39.7
41 to 50 41 28.1
51 to 60 18 12.3
61 to 70 10 6.8
≥ 71 2 1.4
Missing 2 1.4
Transmission category
Heterosexual 75 51.4
Homosexual/bisexual 20 13.7
Intravenous drug use 48 32.9
Blood transfusion 1 0.7
Missing 2 1.4
CD4 count (individual-month)
Stage 1: CD4 ≥ 500 342 25.3
Stage 2: 500 ≤ CD4 < 200 545 40.3
Stage 3: 200 ≤ CD4 < 50 371 27.5
Stage 4: 50 ≤ CD4 93 6.9
CD4 count at detection (mean 
value)
292.33
ART medicationa
NRTI (TDF/FTC, AZT/3TC, 
TDF)
133 91.1
NNRTI (EFV, NVP) 53 36.3
PI (LPV, RTV, ATV) 83 56.8
FI (T-20) 1 0.7
II (Raltegravir) 5 3.4
Detection setting
Hospital 79 54.1
Primary Care Center 30 20.6
CAT/CAD 20 13.7
Other 10 6.8
Missing 7 4.8
Number of comorbidities in 
previous years
0 92 63.0
1 35 24.0
> 1 19 13.0
3TC: lamivudine; ATV: atazanavir; AZT: zidovudine; CAT: 
Centro para Atendimento de Toxicodependentes (Center for 
Intravenous Drug Users); CAD: Centro de Atendimento e 
Detecção Precoce (Center for HIV Testing and Counselling); 
EFV: efavirenz; FTC: emtricitabine; LPV: lopinavir; NNRTI: 
non-nucleoside reverse-transcriptase inhibitor; NRTI: 
nucleoside reverse-transcriptase inhibitor; NVP: nevirapine; 
PI: protease inhibitor; RTV: ritonavir; TDF: tenofovir.
a The most common drugs reported in order of frequency
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As regards yearly average costs per stage of disease, 
patients with more than 500 CD4 cells/µl experienced 
an € 11,901 average cost, which increased as the CD4 
count decreased (Table 3, Figure). The highest costs were 
observed for the most severely-affected patients (CD4 
count < 50 cells/µl), reaching € 23,351/patient/year. 
While the costs with hospitalization were non-existent 
in the first stage, they increased in the final stage to an 
average € 7,815/patient/year (33.0% of total costs). 
ART drugs represented the major cost driver at all 
stages, although to a lesser extent in the last stage of 
disease (40.0% of total costs) compared to other stages 
(always more than 60.0% of total cost). ART costs 
were stable across CD4 strata. Specialist consultations, 
exams, one-day care and other drugs represented 10.0% 
or less of total costs. Cost increases were small between 
stage 2 and stage 3 except for one-day care. Major 
increases occurred in the final stage.
Multivariate analysis indicated that average costs were 
not significantly related to any parameter except stage 
of disease, with a significantly higher cost at the final 
stage (Table 4). Adjusting for other factors, we do 
not observed any significant cost differences between 
stages of disease except for the most severely-affected 
patients. Cost progression across stages could not be 
considered as significant, except for stage 2 where costs 
were higher than for stage 3.
DISCUSSION
The average treatment cost was € 14,277/year, mostly due 
to ART drugs (67.0%), followed by HIV consultations 
(9.0%), inpatient care (8.0%) and other drugs (7.0%). 
Although the weight of hospitalization costs was 
substantially higher for the most severely-affected 
patients (33.0%), ART was always the major cost driver 
(40.0%), which was stable across severity groups. Costs 
significantly increased to € 23,351 for patient with a 
CD4 count below 50 cells/µl. No significant differences 
were observed across patient groups, namely age, 
sex, presence of previous comorbidities and place of 
detection. The only statistically significant difference is 
related to the stage of disease.
Average yearly treatment costs (€ 15,293 at 2012 
prices)h for Portugal are lower than those obtained 
for France13 (€ 21,592 at 2012 prices) and Germany9 
(€ 25,526 at 2012 prices). They are also lower than those 
obtained for Switzerland (€ 22,458 at 2012 prices), but 
are similar to those in the US (€ 18,565 at 2012 prices), 
and Italy (€ 15,426 at 2012 prices).1,6,14 However, the 
last three studies rely on older data and thus refer to 
older and cheaper treatments.
Despite the difficulty in comparing studies with 
different methodologies and populations, a rough 
comparison with French data can provide some 
useful insights, given that both studies use recent 
information.5,13 The major discrepancy is driven by 
the last stage of disease (average cost of € 25,013 
for Portugal, € 38,014 for France, in 2012 prices), 
essentially due to differences in hospitalization 
costs (€ 8,371 versus € 15,586, in 2012 prices). This 
discrepancy is certainly due in part to differences in 
severity between patients in the final stage of disease; 
our sample does not include any patient who died 
during the study period, while this was the case for 
more than 2,000 individuals-month in Sloan et al.13 
These cases represent by far the highest expenditures. 
The low average number of inpatient stays in our study 
(0.25 per year); as a comparison point, Caekelbergh 
Table 3. Average costs (€) per patient year and its components,a per stage of disease. Portugal, 2008.
CD4 cells count Total ART drugs
Inpatient 
care
HIV visits
Other 
visits
Other 
drugs
Exams
One-day 
care
Care without 
ART
> 500 11,901 9,199(77) 0(0) 1,061(9) 79(1) 770(6) 723(6) 69(1) 2,273
201 to 500 13,538 9,282(69) 1,011(7) 1,337(10) 72(1) 897(7) 848(6) 90(1) 3,435
51 to 200 15,279 10,514(69) 923(6) 1,401(9) 68(0) 810(5) 1,020(7) 543(4) 3,428
≤ 50 23,351 9,268(40) 7,815(33) 1,888(8) 182(1) 2,480(11) 1,515(6) 202(1) 4,216
All 14,277 9,598(67) 1,199(8) 1,323(9) 80(1) 950(7) 910(6) 217(2) 3,193
Mean resource useb – – 0.25 4.55 1.78 – – 0.51 –
ART: antiretroviral therapy
a Values between brackets indicate the percentage of total costs.
b Mean value for each item (i.e., average number of inpatientstays, HIV consultations, other consultations and one-day care 
episodes). Non-available values are those that refer to very heterogenous services that it would not make sense to aggregate 
into a single value.
h All values from our study and references have been converted to 2012 Euros to allow for comparison. We used inflation rates from: Organization 
for Economic Co-Operation and Development. OECD.StatExtracts: monthly comparative price levels [cited 2013 Apr 5]. Available from: http://
stats.oecd.org/Index.aspx?DataSetCode=CPL# and conversion rates from: XE Currency Converter [website]. [cited 2013 Apr 5]. Available from: 
http://www.xe.com/currencyconverter/
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et ala find average values that are higher for all CD4 
count groups except 351-500 cells/µl (other papers do 
not provide information on resource use).
Other discrepancies are worth noticing. HIV consultations 
in France are mostly performed through one-day care, 
the unit costs of which are higher than usual visits; this 
is a relevant difference with Portugal (HIV consultations 
represent on average € 1,453, for € 2,417 for one-day 
Table 4. Regression results for mean cost. Portugal, 2008.
Variable Estimate Standard error
Intercept 9.752a 0.27
Age categories
age1 -0.164 0.18
age2 0.059 0.12
age3 -0.061 0.13
> 1 comorbidity -0.086 0.13
Male -0.007 0.11
Detection setting
Hospital 0.038 0.18
Primary care center 0.041 0.20
CAT/CAD 0.038 0.22
Other
Stage of disease (CD4 count) Reference category
> 500 -0.281a 0.12
201 to 500 0.025 0.11
51 to 200 0.038 0.11
≤ 50 0.390a 0.14
Hospital Not reported
N 132
Akaike Information Criterion 221.08
Bayesian Information Criterion 270.60
CAT: Centro para Atendimento de Toxicodependentes (Center 
for Intravenous Drug Users);
CAD: Centro de Atendimento e Detecção Precoce (Center for 
HIV Testing and Counselling)
a Significance for two tailed tests are shown as p < 0.05. 
The smaller sample is due to observations with missing 
values being withdrawn.
care in France, at 2012 prices). ART drugs also represent 
a substantially higher burden in France (€ 14,909 versus 
€ 10,281, at 2012 prices, or 74% versus 67% in Portugal). 
A potential explanation, considering the similarity of 
unit costs, could be that Sloan et al13 estimate ART costs 
through modelling, using six ART regimens. Our data 
reflect a variety of regimens (29) in real practice and 
account for potential compliance problems.
The major limitation of the study is the sample size. 
Due to the absence of electronic records, we limited 
our study to a sample of 150 HIV-infected people who 
were followed retrospectively during one year. The 
advantage of this procedure was the ability to collect 
large and exhaustive information for each patient, 
which render our data highly reliable. The limited 
sample explains the lack of significant variations 
across patients’ characteristics, despite the use of 
sophisticate econometric methods. A larger sample 
would have increased the probability of including more 
severe cases, e.g., patients who died during the study 
period, avoiding a potential source of under-estimation. 
Considering a longer period could help assess the 
impact of rapid changes in treatment patterns.
Direct treatment costs for HIV in Portugal are 
comparable to, or slightly lower than, those observed 
in other high-income countries. As expected, ART is 
the main cost driver, which is relatively stable across 
severity groups. The high burden related to ART at all 
stages of disease is counterbalanced by the substantially 
lower inpatient costs compared with other countries. 
Inpatient costs, however, increase dramatically with 
severity of disease, arguing in favor of keeping patients 
at low-severity stages of disease for as long as possible. 
The relatively modest progression of total costs 
highlights that alternative public health strategies that 
do not affect transmission of disease may only have a 
limited impact on expenditures, since treatment costs 
are largely dominated by ART costs that are constant 
across stages of disease.
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